VERNON HILLS, Ill.--(BUSINESS WIRE)--Applied NeuroSolutions, Inc. (OTCBB:APSN)(www.AppliedNeuroSolutions.com), a biotechnology company focused on the development of products for the early diagnosis and treatment of Alzheimer's disease ("AD"), today announced that Eli Lilly and Company (NYSE:LLY) has agreed to a one-year renewal of its drug discovery collaboration. Lilly will pay $250,000 to Applied NeuroSolutions for the one-year collaboration renewal.
